Abstract Library

#2928 Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumour (NET) Patients (SCAN) – Assessment of Early Diagnosis

Introduction: SCAN measured global readiness to provide diagnostics and treatments for NET patients in terms of awareness, availability, quality and affordability.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Van Genechten D

Authors: Van Genechten D, McDonnell M, Rodien-Louw C, Dureja S, Leyden S,

Keywords: Neuroendocrine Tumours, Survey, Earlier diagnosis,

#2713 The Economic Impact to Patients with Neuroendocrine Tumours

Introduction: The quality of life impact on patients with neuroendocrine tumours (NETs) and the economic burden on health systems are substantial. However, little is known about the economic burden to individual patients and families for medical out-of-pocket expenses and employment decisions.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Wyld D

Authors: Wyld D, Elliott T, Wakelin K, Leyden S, Leyden J,

Keywords: Financial Toxicity, Economic impact, Quality of Life, NETs,

#2701 Assessing the Gaps in Experience and Knowledge of Australian Primary Health Care Professionals (GPs), in Treating and Caring for the Increasing Number of Australian Neuroendocrine Tumour (NET) Patients

Introduction: Conservatively,the incidence of NETs is 7 / 000' p.a, however,the prevalence of patients living with NETs is higher,40/000',making it the 2nd most common GI malignancy after colorectal cancer.Patients are living longer,however,with impaired quality of life.Management of debilitating symptoms such as diarrhoea,fatigue,anxiety,and flushing are complex and heterogenous.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Leyden S

Authors: Leyden S, Cummins M, Wakelin K,

Keywords: diagnosis, ongoing care, primary healthcare, NETs, quality of life, symptom management, NET symptoms,

#1220 Time to Diagnosis of Neuroendocrine Tumors (NETs): Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals

Introduction: Diagnosis of NETs often occurs late in the disease course, which may have an impact on pt survival. We present pt-reported data on time to diagnosis in global NET pts.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Pavel M, Goldstein G, Sissons M, Kolarova T, Leyden J,

Keywords: Diagnosis,

#1217 The Neuroendocrine Tumor (NET) Patient (pt) Perspective: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals

Introduction: Despite a rising incidence of NETs, few studies document the NET pt experience. We present data on quality of life (QoL) and the global NET pt perspective.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Leyden J, Sissons M, Goldstein G, Kolarova T, Bouvier C,

Keywords: Quality of life,